心血管风险对强化降压相对获益与危害的影响
基于SPRINT试验,按基线10年心血管病风险四分位分层分析强化降压的获益与危害。结果显示各四分位强化组主要结局事件率均更低且全因严重不良事件无差异,但需治疗人数从91降至38、需伤害人数从62升至250,获益-危害比随风险升高而显著增加。
要点
- 低危患者强化降压危害大于获益,高危患者获益大于危害。
- 随心血管风险升高,获益-危害比显著递增(趋势P<0.001)。
- 该分析可辅助医患决策降压治疗强度。
核心结论
- 基线心血管风险较低者强化降压危害多于获益,风险较高者获益多于危害。
研究设计与样本
- 基于SPRINT试验人群,按基线10年心血管病风险四分位分层,采用Cox比例风险模型分析治疗组与主要结局事件及严重不良事件的关联,并用乘法Poisson回归构建获益-危害比预测模型。
主要发现
- 各四分位内强化治疗组主要结局事件率均更低,全因严重不良事件无差异。
- 从第一至第四四分位,预防主要结局的需治疗人数从91降至38。
- 从第一至第四四分位,全因严重不良事件的需伤害人数从62升至250。
- 获益-危害比(±SE)分别为0.50±0.15、0.78±0.26、2.13±0.73、4.80±1.86(趋势P<0.001)。
- 四分位间获益-危害比均值的所有两两比较均显著不同(P<0.001)。
临床怎么用
- 可结合患者基线10年心血管病风险分层,评估强化降压的获益与危害平衡。
- 对低危患者需谨慎权衡强化降压的潜在危害,对高危患者可更积极考虑强化治疗。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The lower rate of primary outcome events in the intensive treatment group in SPRINT (Systolic Pressure Intervention Trial) was associated with increased clinically significant serious adverse events (SAEs). In 2017, the American College of Cardiology/American Heart Association issued risk-based blood pressure treatment guidelines. The authors hypothesized that stratification of the SPRINT population by degree of future cardiovascular disease (CVD) risk might identify a group which could benefit the most from intensive treatment. OBJECTIVES: This study investigated the effect of baseline 10-year CVD risk on primary outcome events and all-cause SAEs in SPRINT. METHODS: Stratifying by quartiles of baseline 10-year CVD risk, Cox proportional hazards models were used to examine the associations of treatment group with the primary outcome events and SAEs. Using multiplicative Poisson regression, a predictive model was developed to determine the benefit-to-harm ratio as a function of CVD risk. RESULTS: Within each quartile, there was a lower rate of primary outcome events in the intensive treatment group, with no differences in all-cause SAEs. From the first to fourth quartiles, the number needed to treat to prevent primary outcomes decreased from 91 to 38. The number needed to harm for all-cause SAEs increased from 62 to 250. The predictive model demonstrated significantly increasing benefit-to-harm ratios (± SE) of 0.50 ± 0.15, 0.78 ± 0.26, 2.13 ± 0.73, and 4.80 ± 1.86, for the first, second, third, and fourth quartile, respectively (p for trend <0.001). All possible pairwise comparisons of between-quartile mean values of benefit-to-harm ratios were significantly different (p < 0.001). CONCLUSIONS: In SPRINT, those with lower baseline CVD risk had more harm than benefit from intensive treatment, whereas those with higher risk had more benefit. With the 2017 American College of Cardiology/American Heart Association blood pressure treatment guidelines, this analysis may help providers and patients make decisions regarding the intensity of blood pressure treatment.
引用
- Phillips RA, Xu J, Peterson LE, et al. Impact of Cardiovascular Risk on the Relative Benefit and Harm of Intensive Treatment of Hypertension. J Am Coll Cardiol. 2018. PMID: 29525494. doi:10.1016/j.jacc.2018.01.074
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。